Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course What is a Patient Blood Management Program? (by ASCLS). Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about What is a Patient Blood Management Program? (by ASCLS) (online CE course) »
How to Subscribe
Individual course$30 Add to cart
Individual course$30 Add to cart

Disadvantages of Hemostatic Agents

Factor concentrates including recombinate activated factor VII (rFVIIa), three and four factor prothrombin concentrates and fibrinogen concentrates may be used in massive transfusion events. The use of some of these concentrates in massive transfusion may be considered "off-label" as the product circular does not include this indication.

One major concern with the use of these drugs is the unintentional intravascular clotting leading to stroke. There may be cautions specific to a drug such as the contraindication for patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity.

Cryoprecipitate and other agents incorporating thrombin or fibrin may be used topically at the point of bleeding to stop or reduce bleeding.

Blausen.com staff. "Blausen gallery 2014". Wikiversity Journal of Medicine. DOI:10.15347/wjm/2014.010. ISSN 20018762. (Own work) [CC-BY-3.0 (http://creativecommons.org/licenses/by/3.0)], via Wikimedia Commons